In 208 children with opsoclonus-myoclonus syndrome (OMS), CSF IgG oligoclonal bands (OCB) and 22 immunomarkers in CSF and 21 in serum/blood were measured. In 36 untreated OMS, 58% were OCB(+), whereas 55% of treated OMS were OCB(−). OCB positivity or negativity did not alter concentrations or frequencies of immunomarkers. The phenotypes of OCB(+) and OCB(−) patients were not distinctive. CSF B cells were expanded in untreated OMS regardless of OCB positivity. These data reveal a much higher frequency of OCB positivity in untreated OMS than previously realized and a disconnect between intrathecal OCB and inflammatory mediator production.
Introduction
Cerebrospinal fluid (CSF) oligoclonal bands (OCB) are found across the gamut of neuroinflammatory disorders, for which they provide an index of clonal B cell intrathecal response to a CNS antigen (Krumbholz and Meinl, 2014) . They are indicative of the importance of activated B cell subsets to the earliest clinical stages and potential risk posed for disease progression, even being called "B cell surrogates." The frequency of OCB(+) patients varies with the diseases characterized by intrathecal immune response and between individuals with the same disease type (Achiron et al., 2012; Lin et al., 2012; Reiber et al., 2009 ). OCB(−) patients with multiple sclerosis have been the subject of considerable interest. Genetic differences have been proposed as the basis of whether a patient is OCB(+) or OCB(−) (Lundkvist et al., 2010) .
Likewise, intrathecal overproduction of chemokines, such as CXCL13, CXCL10, and CXCL12, that attract lymphocytes to inflammatory sites have been found in a variety of disorders ranging from multiple sclerosis to neuropsychiatric lupus and many other autoimmune diseases (Maimone et al., 1991; Ichinose et al., 2015) . Combinatorial assay panels utilizing multiple markers have aided mapping the patterns of inflammatory mediators (Edwards et al., 2013) , including those that foster the survival of B cells and plasma cells in niches within the CNS (Pollok et al., 2017) . While OCB production and chemokine/cytokine production has been compared in adults with multiple sclerosis (Vrethem et al., 2012) , few other neuroinflammatory disorders have been interrogated in the same way, especially in children, and require elucidation.
Opsoclonus-myoclonus syndrome (OMS) is a neuroinflammatory neurological disorder that affects children and adults, giving rise to the motor triad of opsoclonus, myoclonus, and ataxia in classic cases and the non-motor cluster of acute irritability, insomnia, and encephalopathy. Later, neuropsychiatric involvement may manifest as attention deficit disorder, behavioral problems, and cognitive impairment. OMS relapse occurs in the majority. In children, OMS can be demonstrated to be paraneoplastic in one-half of the cases in association with neuroblastic tumors. In the others, which bear the same clinical phenotype, spontaneous tumor regression or para/post-infectious etiologies have been inferred (Pranzatelli and Tate, 2018) .
Our early data, obtained primarily from treated patients, showed that elevated CSF OCB correlated with OMS severity and decreased with combination immunotherapy (Pranzatelli et al., 2011) . However, there were not enough untreated patients to allow phenotypic comparison between OCB(+) vs OCB(−) groups, and the sample of treated patients was insufficient for analysis of individual treatment agents. The present study represents an update in a doubled sample size sufficient for further secondary analysis. The idea was to determine whether OCB counts/frequency and secondary mediator concentrations in CSF and serum/blood sort together or independently. There has been no other such study in pediatric paraneoplastic neurological disorders.
The aims of this retrospective study were multiple. First, we wanted to test the hypothesis that CSF OCB presence is related to intrathecal inflammation at the time of diagnosis (before immunotherapy) as quantitatively assessed by 10 chemokines/cytokines, including those involved in B cell trafficking and differentiation; 6 lymphocyte subsets; QIg, IgG index, Qalbumin, and other tests. Second, we pursued the observation that immunotherapy reduces the number of CSF OCB by breakout of individual immunotherapeutic agents and combinations in a larger sample. Third, we performed frequency analysis of OCB(+) and OCB(−) patients with respect to the above parameters.
Patients and methods

Study design
Through the National Pediatric Myoclonus Center, the largest international center for pediatric-onset OMS, 208 children with OMS were recruited from 2007 to 2012. Parents signed informed consent for enrollment of their child in this IRB-approved case-control, cross-sectional, observational study of immunological abnormalities in OMS (SIU School of Medicine, Springfield, IL). Per protocol, clinical and demographic data as well as extra CSF and blood/serum/plasma were obtained for chemokine/cytokine, lymphocyte, and other immunological studies at the time of diagnostic evaluation, which included a lumbar puncture.
Data on 24 children treated with FLAIR therapy (ACTH, IVIg, and rituximab) were analyzed retrospectively via exempt review status granted by Western Institutional Review Board (Wallup, WA). The choice of treatment modality was empirical, not part of a clinical drug trial. Due to the very high rate of serious morbidity in OMS, we introduced into our clinical practice retesting for neuroinflammation after immunotherapy, subsequently known as testing for freedom from disease activity (Havrdova et al., 2010) or no evidence of disease activity (Nixon et al., 2014) . Parents were reconsented.
Patients and controls
Special precautions in the atraumatic collection of CSF and blood in pediatric-onset OMS have been described previously (Pranzatelli et al., 2004; Pranzatelli et al., 2008; Pranzatelli et al., 2012) . Patients were videotaped with written parental consent at the initial evaluation, and videos were scored by an experienced blinded observer using a validated 36-point, 12-item severity scale, as an objective measure of OMS severity (Pranzatelli et al., 2004) . The standard clinical designations based on Total Score were mild (0−12), moderate (13-24), and severe (25-36).
Of "All OMS," the mean overall age was 4.0 ± 3.6 years; in the OCB (+), 3.9 ± 3.8 years; in the OCB(−), 4.1 ± 3.5 years. In untreated OMS (n = 36), 50% of the patients were males and 50% were females, and the mean age was 2.4 ± 1.1 years.
Case controls consisted of 43 children with non-inflammatory neurological or psychiatric disorders. Fifty-six percent were males; 44%, females. The mean age with SD was 6.9 ± 5.7 years.
ELISA
ELISA assays were performed on CSF and serum collected on ice and stored at −80°C in the biorepository of the National Pediatric Myoclonus Center. Assays were run in duplicate on batched samples representing the various clinical groups in the Pranzatelli lab as described before using commercial kits for CCL19 (Pranzatelli et al., 2013c) ; CXCL12 and CXCL13 (Pranzatelli et al., 2012) ; CXCL9 and CXCL10 (Pranzatelli et al., 2013d) ; BAFF (Pranzatelli et al., 2008) ; IL-6, sIL-2Ra, sICAM-1 (Pranzatelli et al., 2013b) ; and IL-17 and sCD14. Our reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum in children with non-inflammatory neurological disorders have been published (Pranzatelli et al., 2013a) .
Flow cytometry
CSF was collected on ice and brought promptly to the flow cytometry lab, where the cells were stained within an hour after collection. Lymphocyte subsets were analyzed in fresh CSF and blood ex vivo by flow cytometry using published methods (Pranzatelli et al., 2004) . The percentage of CD3(+) T cells, CD4(+) T cells, CD8(+) T cells, NK cells, TCR γδ (+) T cells, and CD19(+)CD3(−) B cells was analyzed.
Oligoclonal band and other assays
Isoelectric focusing with immunofixation was performed on CSF and paired serum samples by ARUP Laboratories (Salt Lake City, UT) under the oligoclonal band profile test (Catalog # 0080440), using the Hydragel 9 Cerebrospinal Fluid Isofocusing Kit and the semi-automated Hydrasys System (Sebia, Norcross, GA). Samples, diluted to equivalent IgG concentrations, were run side-by-side. Per the reference laboratory, OCB were considered positive if ≥2 extra IgG bands were found in CSF than in a paired, simultaneously collected, serum sample. Immunoglobulins were quantitated using the BN II Nephelometer (Siemens Dade Behring, Schwalbach, Germany). CSF lymphocyte count and differential were done manually at the Clinical Lab.
Data handling and statistics
Data analysis was performed using GraphPad Prism Version 7.02 (San Diego, CA). The data were dichotomized/stratified as OCB(+) vs OCB(−). Dependent variables included chemokine/cytokine concentration, lymphocyte subset frequencies, and quantitative immunoglobulin concentration. Quantified data are displayed showing both the mean and median. Hence, the main analysis was performed using parametric statistics, with additional non-parametric tests with small sample size comparisons as necessary. Specifically, ANOVA with Turkey multiple comparisons test and Bonferroni corrections for multiple comparisons were performed on individual immunotherapies as well as on bundled treatments. The 2-tailed t-test was used for twogroup unpaired data. If medians were analyzed, the Kruskal Wallis test with Dunn multiple comparisons ad hoc test were utilized. Frequency analysis utilized Chi-square or Fisher's exact test. Correlation analysis employed Pearson correlations (r). Comparisons of pre-and posttreatment OCB counts were made by a paired t-test. Statistical significance was set at p < 0.05.
Results
OCB relation to OMS severity in "All OMS"
Of "All OMS," 36% were OCB(+), 64% OCB (−). Fifteen percent of patients were untreated, 20% were not on treatment at evaluation but had been treated previously, and 63% were actively being treated with immunotherapy. Monotherapy comprised 39% of the active treatment group; more than one agent, 61%. In contrast, all controls were OCB negative; 1 had a single IgG band. OCB differed quantitatively across OMS clinical severity gradations (p < 0.0001).
Frequency analysis showed a parallel, in that the percentage of OCB (+) patients increased with greater OMS severity (higher Total Score) and the frequency of OCB(−) patients decreased. At each level of OMS severity, a comparably low percentage of OCB single bands were found.
Cross-sectional comparison of CSF OCB based on treatment status
For the group of patients on any treatment at the time of evaluation (Fig 1A) , 38% had ≥2 OCB, 15% had 1 OCB, and 55% had 0 OCB. In untreated patients as a group, 58% had ≥2 OCB; 8%, 1 OCB; 33%, 0 OCB. These differences were statistically significant (p < 0.0001, Chisquare). Put into perspective, 58% of untreated OMS were OCB (+), whereas 55% of treated OMS were OCB (−).
OCB relation to OMS severity in untreated OMS
In untreated OMS (n = 36), no statistically significant relation between the quantity of CSF OCB and Total Score categories was found, but OCB counts were significantly greater in severe OMS (p = 0.02, Chisquare). The number of CSF OCB did not correlate with Total Score (r = −0.21, p = 0.22). Frequency analysis (Fig 1B) revealed a high percentage of OCB(+) patients at each severity level (57% for mild and 73% for severe).
OCB relation to oms severity in treated oms
The frequency of OCB(t) patients increased with oms severity ( Fig  1C) . In the monotherapy subgroup (Fig 1D) severe oms was associated with a higher OCB(+) frequency than in the multitherapy subgroup (Fig 1E) . Previously treated oms was similar to untreated OMS in the moderate and severe categories (Fig 1F) . In an analysis of treated OMS by mono-vs multitherapy at evaluation, 34% of patients on monotherapy (n = 50) were OCB(+), compared to 27% in the multitherapy group (n = 78).
OCB etiology and OCB frequency
In a secondary breakdown of treated OMS by tumor history, the frequency of OCB(+) patients was 27% in the tumor group (n = 74) and 33% in the no-tumor group (n = 54), which was not statistically different.
OCB relation to CSF B cell frequency in untreated OMS
Of OCB(+) patients, 90% had elevated CSF B cell frequency (10% did not). Even in OCB(−) patients, 93% had elevated CSF B cell frequency. In all, 91% of untreated patients were CSF B cell expanded; 57% were OCB(+) (Fig. 1G) .
3.7. OCB relation to OMS duration in "All OMS" OMS duration category (Fig. 1H ) did not correlate with the number of CSF OCB (p = 0.11, ANOVA) or the frequency of OCB(+) patient (p = 0.19, C-S). The mean OCB counts were 2.8, 1.8, and 1.8 in the 3-level duration categories, whereas the medians were 1.0, 0, and 0, respectively. The frequency of OCB(+) patients was 43%, 40%, and 31% across the duration categories. The corresponding frequency of OCB(−) patients was 57%, 60%, and 69%.
Cross-sectional comparison of immunotherapy effects on CSF OCB
There was a statistically significant main effect of immunotherapy on mean or median CSF OCB counts ( Fig. 2A) . When individual agents or combinations were compared to uOMS, only two groups, in which mean OCB counts were < 2, were statistically significant (not robustly). IVIg appeared to exhibit the least effect. However, the mean CSF OCB count was significantly lower in all treated groups combined (1.5 ± 2.1 SD) compared to uOMS (3.9 ± 4.2) (p < 0.0001, t-test) (Fig. 2B) .
The significance of the number of immunotherapy agents on CSF OCB also was tested (Fig. 2B) . With two-agent (dual) and multiple agent treatments, not monotherapy, the number of CSF OCB was significantly lower than in uOMS.
When groups were bundled instead based on ACTH or steroid (Fig. 2C) , the mean number of OCB differed significantly between untreated OMS and "All ACTH" (***) and untreated OMS and "All Steroid" (**), whereas the mean count differed only between untreated OMS and "All ACTH" (***). "All A" and "All S" also included rituximab, cyclophosphamide, or other agent.
Retrospective analysis of FLAIR combination treatment effects
In the 24 patients treated empirically with FLAIR therapy, there was a significant reduction (−78%) in the number of OCB (p = 0.001, Fisher's test) (Fig. 2D) . In the 3 patients who still had positive OCB posttreatment, the OCB dropped from 10 to 7, 9 to 6, and 6 to 2, respectively.
The percentage of OCB(+) patients also decreased by 75% (p < 0.0001). All OCB(−) patients at the start remained OCB(−) (Fig. 3C) .
4. Cross-sectional comparison of immunotherapy effects on frequency of OCB(+) and OCB(−) patients in untreated OMS When the overall effect of individual immunotherapies or treatment combinations was analyzed by Chi-square (Fig. 3A) , the statistical significance was minimal. The lowest frequency of OCB(+) patients was 15%; in the IVIg monotherapy group, it was highest at 42%. Of symptomatic patients treated previously but not at the time of evaluation, 39% were OCB(+).
However, when the treatments were bundled into multi-agent combinations, the statistical significance strengthened. In both "All ACTH" or "All Steroid" bundled treatment groups (Fig. 3B) , the frequency of OCB(+) patients declined and the frequency of OCB(−) patients increased. Both subgroups would have included rituximabtreated patients.
OCB resolution with treatment: case study
Visual inspection of a gel containing three CSF samples over time from one patient shows the rapid decline in OCB (Fig. 4) . Six OCB resolved and 1 persisted by the time of the last observation.
OCB vs chemokines and adhesion molecules that discriminated OMS from controls in untreated OMS
Six chemokines and one soluble adhesion marker differentiated controls and either OCB(+) or OCB(−) OMS (Fig. 5) . However, the marker concentrations were not significantly different between the OCB (+) and OCB(−) subgroups. Additional analysis was performed on other CSF chemokines, non-chemokine cytokines, a microglial marker, an adhesion molecule, leukocyte count with differential, lymphocyte subsets, Qalbumin, and IgG concentration and index (Table 1) . No statistically significant differences between OCB(+) and OCB(−) OMS was found. A similar analysis of serum/blood immunomarkers also did not differentiate the two OCB subgroups (Table 2) .
Discussion
This report provides several new observations and an update of previous results from early data. Each will be individually addressed.
First, the frequency of intrathecally-produced OCB was much higher in untreated OMS than previously recognized from the study of treated patients, which showed only 35% positivity (Pranzatelli et al., 2011) . The 58% OCB positivity stands below the 85-95% OCB frequency of multiple sclerosis (Karrenbauer et al., 2013) and neuromyelitis optica, but above that for the 10-40% frequencies in Sydenham chorea, neuropsychiatric lupus, autoimmune encephalitis, transverse myelitis, and acute disseminated encephalomyelitis (Atzori et al., 2009) . Intrathecal OCB were positive in 19% of inflammatory pediatric CNS disorders, but negative in 142 non-inflammatory pediatric controls (Sinclair et al., 2013) . The utility of CSF OCB testing in OMS is therefore enhanced, placing it above that for CSF leukocytosis (Pranzatelli and Tate, 2018) .
Second, this study affords a point of comparison with CSF-confined OCB in other paraneoplastic syndromes. In a retrospective study of 135 adults with paraneoplastic syndromes, OCB were found in the CSF in 63%, and were the only CSF abnormality in 10% (Psimaras et al., 2010) . In other published series of adult-onset paraneoplastic neurological syndromes for which there are known autoantibodies, OCB presence in CSF has been reported in about 75% of patients. These include anti-Hu (ANNA-1) (Dalmau et al., 1992) , anti-Yo (anti-PCA-1) (Peterson et al., 1992) , and anti-Ma2 (Dalmau et al., 2004) . OCB specificity against the paraneoplastic antigen has been demonstrated for anti-HuD (Rauer and Kaiser, 2000) and anti-amphiphysin and anti-CV2/CRMP5 (Stich and Rauer, 2007) . In 4 of 6 children with paraneoplastic limbic encephalitis, CSF OCB were positive (Honnorat et al., 2013) . More OCB studies of pediatric-onset paraneoplastic disorders are needed.
Third, lack of correlation with OMS duration suggests that CSF OCB production persists longer than several inflammatory mediators, at least during the study observation period, up to 3-5 years in relapsing patients. Thus, OMS duration is not likely to be a variable in interpreting drug effects on OCB. Also, in the whole OMS dataset, tumor was not less common in OCB(+) patients.
Fourth, CSF OCB decreased with immunotherapy, but most significantly with multimodal therapy. As there is no consensus on the treatment for OMS, clinicians have used single agents, 2-agent combinations, and > 3-agent combinations. Early data showed reduction in OCB with FLAIR treatment in 17 patients (Pranzatelli et al., 2011) . In multiple sclerosis, most treatments have little effect of CSF OCB, with the exception of natalizumab (Von Glehn et al., 2012) , which results in complete or partial disappearance of OCB after two years of therapy (Mancuso et al., 2014) . Lack of targeting of plasma cells is thought to explain the minimal effect of rituximab on OCB in multiple sclerosis. However, in OMS, there is OCB reduction with rituximab-based multimodal immunotherapy, though the frontline therapy prevents the exact role of rituximab within the combination from being identified.
Fifth, in untreated OMS, no statistically significant differences in chemokine/cytokine expression based on OCB-positivity were found, an area not previously studied in paraneoplastic neurological disorders or in pediatric neuroinflammatory disorders. We previously showed that OCB sorted with chemokine concentrations only in the "high positive" subgroup (above the median), not the "low positive" subgroup, for CSF CXCL13 (above highest control) (Pranzatelli et al., 2012) , but not CSF CXCL10 (Pranzatelli et al., 2013d) or serum CCL21 (Pranzatelli et al., 2013c) . In adult patients with multiple sclerosis, no cytokine differences were found based on presence or absence of OCB (Maimone et al., 1991) . In another group of adults with multiple sclerosis, the concentrations of 13 cytokines were similar in OCB(+) and OCB(−) patients (Vrethem et al., 2012) . The authors concluded that OCB(−) patients did not seem to constitute a separate entity concerning those inflammatory parameters, which they interpreted as supporting a mainly T-cell-driven mechanism (Vrethem et al., 2012) , but they queried as to whether results for BAFF or CXCL13 might be different. In untreated optic neuritis, six cytokines did not discriminate between OCB(+) and OCB(−) patients (Kivisäkk et al., 1998) . In a recent study comparing 11 OCB(+) and 10 OCB(−) patients with multiple sclerosis (Farina et al., 2017 ) using a 28-plex kit, OCBs were associated with increased concentrations of CXCL13, CXCL12, CXCL10, and IL-6, as well as neurofilament light chain. It may be pertinent that the CSF leukocyte count was elevated only in the OCB(+) cases. CSF CXCL13 was found to be elevated in OCB(+) compared to OCB(−) patients with CIS/RRMS (Puthenparampil et al., 2017) . OMS stands apart from MS by its usual lack of CSF pleocytosis or elevations in the CSF concentrations of APRIL (Fühlhuber et al., 2009 ), CXCL12 (was decreased M.R. Pranzatelli et al. Journal of Neuroimmunology xxx (xxxx) xxx-xxx instead) (Pranzatelli et al., 2012) , CXCL8 (Pranzatelli et al., 2013b) , or sCD163. Although CSF neurofilament light chain was increased in OMS, there was no significant difference in concentration between OCB(+) (n = 39) and OCB(−) patients (n = 60) (Pranzatelli et al., 2014) . Sixth, there is a clinical recommendation for pediatric neurology, in which CSF OCB testing is routine for central demyelinating disorders, but otherwise sporadic. Our data suggest potential as a biomarker of disease activity in paraneoplastic disorders as well as in putative neuroinflammatory disorders.
This study had several strengths. It was very large for an orphan disease and well characterized clinically. Clinical severity was scored using an established validated scale. Multiple parameters of intrathecal immune response were measured, involving both cellular and inflammatory mediators. OCB and chemokine/cytokine measurements were made in respective reference laboratories.
There were also study limitations. Ever larger datasets of untreated OMS are desired for subgroup analysis, but OMS is so rare, and the patient sample we were able to recruit was comparably large. Some individual treatment subgroups are small. Long-term data for correlating CSF OCB counts or frequency with permanent remission of OMS will be necessary. Prospective biomarker validation is requisite.
Conclusions
In this largest pediatric-onset-OMS cohort to date, the data indicate that OCB found in CSF but not in paired serum can be regarded as a separate potential biomarker from chemokine/cytokine inflammatory mediators. The high CSF OCB production in OMS shows ties with some other paraneoplastic neurological disorders in adults. OCB inclusion in a biomarker panel may provide additional disease-discriminating In cross-sectional data from CSF (A-B) and serum (C-F), controls, OCB(−) OMS cases, and OCB(+) OMS cases were compared. Statistical between-group comparisons in OMS were made by t-tests, using Bonferroni corrections (*). There were no statistically significant differences between OCB(+) and OCB (−) groups. potential for monitoring therapy and evaluating disease progression, and may contribute to better therapeutic choices. Clinical trials in pediatric neuroinflammatory disorders measuring OCB prospectively and monitoring its potential as for risk stratification, prognostic, and treatment biomarker and long-term outcome studies are warranted.
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